
Annexon Investor Relations Material
Latest events

Study Result
Annexon

Q1 2025
12 May, 2025

Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Annexon Inc
Access all reports
Annexon, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company focuses on targeting C1q, an initiating molecule of the classical complement pathway, which plays a critical role in various disease processes, including antibody-mediated autoimmune diseases and complement-mediated neurodegeneration. Annexon's pipeline includes several product candidates such as ANX005, which is in clinical trials for Guillain-Barré syndrome, and other trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Annexon is headquartered in Brisbane, California, and its shares are listed on the Nasdaq.
Key slides for Annexon Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Annexon Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Annexon Inc
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ANNX
Country
🇺🇸 United States